Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 1
1997 5
1998 9
1999 57
2000 71
2001 147
2002 209
2003 241
2004 305
2005 388
2006 480
2007 528
2008 554
2009 554
2010 588
2011 609
2012 640
2013 614
2014 615
2015 617
2016 613
2017 613
2018 574
2019 510
2020 418
Text availability
Article attribute
Article type
Publication date

Search Results

8,693 results
Results by year
Filters applied: . Clear all
Page 1
Etanercept for the treatment of rheumatoid arthritis.
Zhao S, Mysler E, Moots RJ. Zhao S, et al. Immunotherapy. 2018 Mar 1;10(6):433-445. doi: 10.2217/imt-2017-0155. Epub 2018 Feb 27. Immunotherapy. 2018. PMID: 29482402 Review.
Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, function, quality of life and mortality for these patients. ...With the increasing number of etanercept biosimilars, there will likely be a
Etanercept, along with other TNF inhibitors, have revolutionized management of RA and dramatically improved disease activity, functio
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
Chadwick L, Zhao S, Mysler E, Moots RJ. Chadwick L, et al. Curr Rheumatol Rep. 2018 Nov 9;20(12):84. doi: 10.1007/s11926-018-0799-0. Curr Rheumatol Rep. 2018. PMID: 30411183 Free PMC article. Review.
PURPOSE OF REVIEW: Etanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the United States (US) and Europe. ...In this article, we review the original trials for etanercept in RA to facilitate critical appraisal of …
PURPOSE OF REVIEW: Etanercept was the first tumour necrosis factor inhibitor approved to treat rheumatoid arthritis (RA) in the Unite …
Biosimilars in rheumatology.
Araújo FC, Gonçalves J, Fonseca JE. Araújo FC, et al. Pharmacol Res. 2019 Nov;149:104467. doi: 10.1016/j.phrs.2019.104467. Epub 2019 Sep 27. Pharmacol Res. 2019. PMID: 31568820 Review.
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab and rituximab biosimilars. ...
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab a …
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.
Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, Kricorian G, Chung JB. Mease PJ, et al. Arthritis Rheumatol. 2019 Jul;71(7):1112-1124. doi: 10.1002/art.40851. Epub 2019 May 28. Arthritis Rheumatol. 2019. PMID: 30747501 Free PMC article. Clinical Trial.
OBJECTIVE: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA). ...Overall, combining methotrexate and etanercep
OBJECTIVE: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotre …
GP2015: An Etanercept Biosimilar.
Deeks ED. Deeks ED. BioDrugs. 2017 Dec;31(6):555-558. doi: 10.1007/s40259-017-0246-1. BioDrugs. 2017. PMID: 28940172 Free PMC article. Review.
GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indications for which reference etanercept is approved, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, …
GP2015 is the second biosimilar of the reference p75 TNF receptor-Fc fusion protein etanercept. It is approved for use in all indicat …
A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature.
Echeverría-García B, Nuño-González A, Dauden E, Vanaclocha F, Torrado R, Belinchón I, Pérez-Zafrilla B; Grupo de estudio BIOBADADERM. Echeverría-García B, et al. Actas Dermosifiliogr. 2017 Mar;108(2):168-170. doi: 10.1016/j.ad.2016.09.004. Epub 2016 Oct 17. Actas Dermosifiliogr. 2017. PMID: 27765165 Free article. Review. English, Spanish. No abstract available.
Etanercept for treating axial spondyloarthritis.
Guillot X, Prati C, Sondag M, Wendling D. Guillot X, et al. Expert Opin Biol Ther. 2017 Sep;17(9):1173-1181. doi: 10.1080/14712598.2017.1347156. Epub 2017 Jul 6. Expert Opin Biol Ther. 2017. PMID: 28682112 Review.
Etanercept is a soluble recombinant TNF receptor fusion protein in this vain. Areas covered: The aim of this review is to summarize the current published data concerning the efficacy and tolerance of etanercept in axial spondyloarthrits. ...Etanercept also de
Etanercept is a soluble recombinant TNF receptor fusion protein in this vain. Areas covered: The aim of this review is to summarize t
Infection risk associated with anti-TNF-α agents: a review.
Murdaca G, Spanò F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F. Murdaca G, et al. Expert Opin Drug Saf. 2015 Apr;14(4):571-82. doi: 10.1517/14740338.2015.1009036. Epub 2015 Jan 29. Expert Opin Drug Saf. 2015. PMID: 25630559 Review.
EXPERT OPINION: Infliximab more so than etanercept appears to be responsible for the increased risk of infections. Re-activation of latent tuberculosis (LTB) infection and the overall risk of opportunistic infections should be considered before beginning TNF-α inhibitor th …
EXPERT OPINION: Infliximab more so than etanercept appears to be responsible for the increased risk of infections. Re-activation of l …
Interchangeability of Biosimilars: A European Perspective.
Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Kurki P, et al. BioDrugs. 2017 Apr;31(2):83-91. doi: 10.1007/s40259-017-0210-0. BioDrugs. 2017. PMID: 28120313
Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.
Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R, Mandich P, Puppo F. Murdaca G, et al. Mod Rheumatol. 2018 May;28(3):417-431. doi: 10.1080/14397595.2017.1366006. Epub 2017 Aug 24. Mod Rheumatol. 2018. PMID: 28837372 Review.
There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept. ...IBD incidence was lower in patients receiving etanercept plus MTX. Intra-articular administration of etanercept se …
There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanerc
8,693 results
Jump to page
Feedback